Literature DB >> 15531548

Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition.

Rossella Elisei1, Barbara Cosci, Cristina Romei, Laura Agate, Pamela Piampiani, Paolo Miccoli, Piero Berti, Fulvio Basolo, Clara Ugolini, Raffaele Ciampi, Yuri Nikiforov, Aldo Pinchera.   

Abstract

The RET protooncogene mutations responsible for multiple endocrine neoplasia type 2 are inherited as autosomic dominant traits. We describe here a novel germline homozygous mutation in exon 15 of the RET gene that determines an amino acid substitution (Ala->Thr) at codon 883. The index case was a 51-yr-old patient with an apparently sporadic form of medullary thyroid cancer (MTC). RET gene mutations screening was performed in exons 10, 11, 13, 14, 15, and 16 by automatic sequence analysis. An unexpected homozygous GCT->ACT point mutation was found at codon 883 in exon 15 and confirmed by restriction analysis (Alu I). The presence of the two chromosomes 10 was confirmed by fluorescence in situ hybridization analysis on lymphocytes. As expected on the basis of the homozygosity of the index case, the parents were consanguineous (second-degree cousins). Eight relatives were further investigated: the mother, two sisters, and the son were positive for heterozygous RET mutation. The mother (82 yr old) showed a nodular goiter but was negative both for basal and pentagastrin stimulated calcitonin. The young son (15 yr old) and the two sisters (63 and 58 yr old) did not show any clinical and/or biochemical sign of MTC. One brother (59 yr old) was negative both for RET mutation and clinical/biochemical examination. The other brother, 56 yr of age, was positive for both homozygous RET mutation and serum calcitonin. When operated, the histological examination of the thyroid showed the presence of MTC and C cell hyperplasia. In conclusion, we identified a new germline RET gene mutation during a routine RET gene screening of an apparently sporadic MTC case. This mutation showed a very low transforming activity as demonstrated by the absence of MTC phenotype in heterozygous subjects. The possibility that the homozygous gene carriers were indeed carrying a germline loss of heterozygosity was excluded by fluorescence in situ hybridization analysis for RET gene performed on lymphocytes derived from one homozygous patient. The analysis of several RET polymorphisms also confirmed the presence of two mutated alleles in MTC affected patients and both mutated and wild-type allele in heterozygous subjects.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15531548     DOI: 10.1210/jc.2004-0312

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma.

Authors:  A L Silva; F Carmo; M M Moura; R Domingues; C Espadinha; V Leite; B Cavaco; M J Bugalho
Journal:  Endocrine       Date:  2015-03-01       Impact factor: 3.633

2.  2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.

Authors:  R Elisei; M Alevizaki; B Conte-Devolx; K Frank-Raue; V Leite; G R Williams
Journal:  Eur Thyroid J       Date:  2012-12-19

3.  Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.

Authors:  R Ciampi; C Romei; L Pieruzzi; A Tacito; E Molinaro; L Agate; V Bottici; F Casella; C Ugolini; G Materazzi; F Basolo; R Elisei
Journal:  J Endocrinol Invest       Date:  2016-08-17       Impact factor: 4.256

Review 4.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.

Authors:  Cristina Romei; Raffaele Ciampi; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2016-02-12       Impact factor: 43.330

5.  RET polymorphisms might be the risk factors for thyroid cancer.

Authors:  Rui-Xue Huang; Fei Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 6.  RET signaling in endocrine tumors: delving deeper into molecular mechanisms.

Authors:  Andrea Z Lai; Taranjit S Gujral; Lois M Mulligan
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

Review 7.  State-of-the-Art Strategies for Targeting RET-Dependent Cancers.

Authors:  Vivek Subbiah; Dong Yang; Vamsidhar Velcheti; Alexander Drilon; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 44.544

8.  Rapid diagnosis of MEN2B using unlabeled probe melting analysis and the LightCycler 480 instrument.

Authors:  Rebecca L Margraf; Rong Mao; Carl T Wittwer
Journal:  J Mol Diagn       Date:  2008-02-07       Impact factor: 5.568

Review 9.  A differential diagnosis of inherited endocrine tumors and their tumor counterparts.

Authors:  Sergio P A Toledo; Delmar M Lourenço; Rodrigo A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2013-07       Impact factor: 2.365

Review 10.  Familial syndromes associated with neuroendocrine tumours.

Authors:  Paweł Gut; Hanna Komarowska; Agata Czarnywojtek; Joanna Waligórska-Stachura; Maciej Bączyk; Katarzyna Ziemnicka; Jakub Fischbach; Elżbieta Wrotkowska; Marek Ruchała
Journal:  Contemp Oncol (Pozn)       Date:  2015-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.